KR101367516B1 - 암치료용 치료제의 조합물 - Google Patents

암치료용 치료제의 조합물 Download PDF

Info

Publication number
KR101367516B1
KR101367516B1 KR1020077013401A KR20077013401A KR101367516B1 KR 101367516 B1 KR101367516 B1 KR 101367516B1 KR 1020077013401 A KR1020077013401 A KR 1020077013401A KR 20077013401 A KR20077013401 A KR 20077013401A KR 101367516 B1 KR101367516 B1 KR 101367516B1
Authority
KR
South Korea
Prior art keywords
butoxyiminomethylcamptothecin
combination
carcinoma
tumor
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020077013401A
Other languages
English (en)
Korean (ko)
Other versions
KR20070091286A (ko
Inventor
사라 자크노엔
마가렛 마 우
리차드 윌리암 베르사체
클라우디오 피사노
로레다나 베스치
Original Assignee
씨그마-토 인더스트리에 파마슈티체 리유니테 에스. 피. 에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36463409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101367516(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 씨그마-토 인더스트리에 파마슈티체 리유니테 에스. 피. 에이. filed Critical 씨그마-토 인더스트리에 파마슈티체 리유니테 에스. 피. 에이.
Publication of KR20070091286A publication Critical patent/KR20070091286A/ko
Application granted granted Critical
Publication of KR101367516B1 publication Critical patent/KR101367516B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
KR1020077013401A 2004-12-15 2005-12-13 암치료용 치료제의 조합물 Expired - Fee Related KR101367516B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63643904P 2004-12-15 2004-12-15
US60/636,439 2004-12-15
PCT/US2005/044993 WO2006065780A2 (en) 2004-12-15 2005-12-13 Combinations of therapeutic agents for treating cancer

Publications (2)

Publication Number Publication Date
KR20070091286A KR20070091286A (ko) 2007-09-10
KR101367516B1 true KR101367516B1 (ko) 2014-02-27

Family

ID=36463409

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077013401A Expired - Fee Related KR101367516B1 (ko) 2004-12-15 2005-12-13 암치료용 치료제의 조합물

Country Status (26)

Country Link
US (1) US8975248B2 (cg-RX-API-DMAC7.html)
EP (1) EP1827437B1 (cg-RX-API-DMAC7.html)
JP (1) JP5345323B2 (cg-RX-API-DMAC7.html)
KR (1) KR101367516B1 (cg-RX-API-DMAC7.html)
CN (1) CN101080227B (cg-RX-API-DMAC7.html)
AT (1) ATE531371T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005316652B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0515774A (cg-RX-API-DMAC7.html)
CA (1) CA2589521C (cg-RX-API-DMAC7.html)
CY (1) CY1112368T1 (cg-RX-API-DMAC7.html)
DK (1) DK1827437T3 (cg-RX-API-DMAC7.html)
ES (1) ES2374828T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20110960T1 (cg-RX-API-DMAC7.html)
IL (1) IL183595A0 (cg-RX-API-DMAC7.html)
MA (1) MA29096B1 (cg-RX-API-DMAC7.html)
MX (1) MX2007007212A (cg-RX-API-DMAC7.html)
NO (1) NO20073552L (cg-RX-API-DMAC7.html)
NZ (1) NZ555370A (cg-RX-API-DMAC7.html)
PL (1) PL1827437T3 (cg-RX-API-DMAC7.html)
PT (1) PT1827437E (cg-RX-API-DMAC7.html)
RU (1) RU2400232C2 (cg-RX-API-DMAC7.html)
SI (1) SI1827437T1 (cg-RX-API-DMAC7.html)
TN (1) TNSN07224A1 (cg-RX-API-DMAC7.html)
TW (1) TW200628151A (cg-RX-API-DMAC7.html)
WO (1) WO2006065780A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200704701B (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140070676A (ko) 2002-09-06 2014-06-10 인설트 테라페틱스, 인코퍼레이티드 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
ES2374828T3 (es) 2004-12-15 2012-02-22 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Combinaciones de agentes terapéuticos para el tratamiento del cáncer.
WO2007014335A2 (en) * 2005-07-27 2007-02-01 The University Of Texas System Combinations comprising gemcitabine and tyrosine kinase inhibitors for the treatment of pancreatic cancer
PT2275103E (pt) 2005-11-21 2014-07-24 Novartis Ag Inibidores de mtor para o tratamento de tumores endócrinos
WO2007094026A1 (en) * 2006-02-17 2007-08-23 Paolo La Colla Prophylactic and/or therapeutic treatment of proliferative and conformational diseases
RU2452492C2 (ru) * 2006-04-05 2012-06-10 Новартис Аг КОМБИНАЦИИ, ВКЛЮЧАЮЩИЕ ИНГИБИТОРЫ Bcr-Abl/c-Kit/PDGF-R TK, ДЛЯ ЛЕЧЕНИЯ РАКА
CA2645633A1 (en) * 2006-04-05 2007-11-01 Novartis Ag Combinations of therapeutic agents for treating cancer
CN101415411A (zh) * 2006-04-05 2009-04-22 诺瓦提斯公司 用于治疗癌症的治疗剂组合
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
EP2060565A1 (en) * 2007-11-16 2009-05-20 4Sc Ag Novel bifunctional compounds which inhibit protein kinases and histone deacetylases
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
CN101837129B (zh) * 2009-03-19 2012-12-12 鼎泓国际投资(香港)有限公司 含cMet抑制剂、HDAC抑制剂与EGFR酪氨酸激酶抑制剂的药物组合物及其应用
US20120114658A1 (en) * 2009-09-15 2012-05-10 John Ryan Treatment of cancer
CN102946879B (zh) * 2010-04-19 2015-04-22 尼基制药公司 一种蛋白酶体抑制剂和镓络合物在制备治疗增殖性疾病的药物中的应用
EP2786755A3 (en) 2010-11-12 2014-10-29 Pharma Mar S.A. Combination therapy with an antitumor alkaloid
CN102731516B (zh) * 2011-04-07 2014-07-02 宁波天衡药业股份有限公司 一类具有抗肿瘤活性的喜树碱衍生物
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
PT3127545T (pt) * 2014-04-04 2020-07-20 Taiho Pharmaceutical Co Ltd Fármaco antitumoral que contém composto de taxano e potenciador de efeito antitumoral
EP3307263A4 (en) 2015-06-15 2019-02-13 NewSouth Innovations Pty Limited PHARMACEUTICAL COMBINATIONS OF ORGANO ARSENOXIDE COMPOUNDS AND MTOR HAZARDS
CN107951888A (zh) * 2017-12-19 2018-04-24 天津科技大学 阿法替尼与10-羟基喜树碱的药物组合及其应用
CN109091480A (zh) * 2018-09-19 2018-12-28 天津科技大学 癌组合物10-羟基喜树碱和克唑替尼治疗肺癌及用途
BR112021011894A2 (pt) * 2018-12-21 2021-09-08 Daiichi Sankyo Company, Limited Composição farmacêutica
CN111789903A (zh) * 2019-04-08 2020-10-20 石小和 治疗尿道癌的药物组合物及其制备方法
CA3158733A1 (en) 2019-11-21 2021-05-27 Pilar Calvo Methods of treating small cell lung cancer with lurbinectedin formulations
CN120695174A (zh) * 2021-07-01 2025-09-26 江苏先声生物制药有限公司 抗人vegf抗体与化药联用在制备治疗卵巢癌的药物中的应用
WO2023165603A1 (en) * 2022-03-03 2023-09-07 Zai Lab (Shanghai) Co., Ltd. Dna-pk inhibitor and combination use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040018988A1 (en) * 1999-03-09 2004-01-29 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Camptothecin derivatives having antitumor activity

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08169825A (ja) * 1994-12-15 1996-07-02 Tanaka Kikinzoku Kogyo Kk 抗癌剤の併用投与方法及び併用可能な抗癌剤
EP0715854B1 (en) 1994-11-11 2003-09-10 Debiopharm S.A. Carcinostatic compositions containing cis-oxaliplatinum and one or more other compatible carcinostatic substances
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
US20020103141A1 (en) * 1998-12-23 2002-08-01 Mckearn John P. Antiangiogenic combination therapy for the treatment of cancer
DK1044977T3 (da) * 1999-03-09 2002-07-08 Sigma Tau Ind Farmaceuti Camptothecinderivater med antitumoraktivitet
GB0119249D0 (en) * 2001-08-07 2001-10-03 Novartis Ag Organic compounds
US20050038048A1 (en) 2001-10-29 2005-02-17 Ball Howard Ashley Use of 7h-pyrrollo{2,3-d}pyrimidine derivatives in the treatment of solid tumor diseases
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
HRP20050115A2 (en) * 2002-07-11 2005-10-31 Combinatorx Combinations of drugs for the treatment of neoplasms
WO2004103358A2 (en) 2003-05-21 2004-12-02 Novartis Ag Combination of histone deacetylase inhibitors with chemotherapeutic agents
CA2569277A1 (en) * 2004-06-04 2005-12-15 Pfizer Products Inc. Method for treating abnormal cell growth
ES2374828T3 (es) 2004-12-15 2012-02-22 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Combinaciones de agentes terapéuticos para el tratamiento del cáncer.
JP4702322B2 (ja) 2006-12-14 2011-06-15 トヨタ自動車株式会社 内燃機関の制御装置

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040018988A1 (en) * 1999-03-09 2004-01-29 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Camptothecin derivatives having antitumor activity

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Cancer Research. January 1, 2004. Vol. 64, pp. 252-261 *
Cancer Research. January 1, 2004. Vol. 64, pp. 252-261*
Cancer Research. July 15, 2004. Vol. 64, pp. 4931-4941 *
Cancer Research. July 15, 2004. Vol. 64, pp. 4931-4941*

Also Published As

Publication number Publication date
TNSN07224A1 (en) 2008-11-21
ES2374828T3 (es) 2012-02-22
CN101080227A (zh) 2007-11-28
IL183595A0 (en) 2007-10-31
CN101080227B (zh) 2011-08-31
US20100028338A1 (en) 2010-02-04
MX2007007212A (es) 2007-11-07
CA2589521C (en) 2014-04-01
PL1827437T3 (pl) 2013-06-28
BRPI0515774A (pt) 2008-08-05
PT1827437E (pt) 2012-01-12
EP1827437B1 (en) 2011-11-02
KR20070091286A (ko) 2007-09-10
US8975248B2 (en) 2015-03-10
WO2006065780A3 (en) 2006-08-17
HRP20110960T1 (hr) 2012-01-31
MA29096B1 (fr) 2007-12-03
NZ555370A (en) 2010-03-26
AU2005316652B2 (en) 2009-07-23
SI1827437T1 (sl) 2012-02-29
WO2006065780A2 (en) 2006-06-22
RU2007126978A (ru) 2009-01-27
JP2008524225A (ja) 2008-07-10
NO20073552L (no) 2007-09-12
AU2005316652A1 (en) 2006-06-22
TW200628151A (en) 2006-08-16
ZA200704701B (en) 2008-09-25
EP1827437A2 (en) 2007-09-05
RU2400232C2 (ru) 2010-09-27
JP5345323B2 (ja) 2013-11-20
ATE531371T1 (de) 2011-11-15
CA2589521A1 (en) 2006-06-22
CY1112368T1 (el) 2015-12-09
DK1827437T3 (da) 2012-02-13

Similar Documents

Publication Publication Date Title
US8975248B2 (en) Combinations of therapeutic agents for treating cancer
Ilson Oesophageal cancer: new developments in systemic therapy
US9918972B2 (en) Treatment of leukemia with artemisinin derivatives and combinations with other antineoplastic agents
HK1252369A1 (zh) 利用纳米颗粒治疗肿瘤的组合物和方法
US20120093809A1 (en) Use of alkanoyl l-carnitine in combination with chemotherapeutic agents for the treatment of neoplasms
KR20220003560A (ko) 유잉 육종의 치료를 위한 퀴놀린 화합물 또는 그의 약제학적으로 허용 가능한 염
CN102753176A (zh) 含有cdc7抑制剂和抗癌药的治疗组合物
MXPA05001430A (es) Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas.
AU2007247112B2 (en) Combination comprising an iron chelator and an anti-neoplastic agent and use thereof
Sun et al. Preclinical activity of lobaplatin as a single agent and in combination with taxanes for ovarian carcinoma cells
Fracasso et al. Phase I study of rubitecan and gemcitabine in patients with advanced malignancies
US20110117212A1 (en) Therapeutic combination comprising an aurora kinase inhibitor and an antineoplastic agent
Quantin 225 Phase I–II study of high dose epidoxorubicin (EPI) plus cisplatin (DDP) in IIIb or IV non-small cell lung cancer (NSCLC): Searching the optimal DDP dosage
HK1161114B (en) Use of alkanoyl l-carnitine in combination with chemotherapeutic agents for the treatment of neoplasms
HK1150028A (en) Combination comprising an iron chelator and an anti-neoplastic agent and use thereof
TW201016214A (en) Synergistic pharmaceutical composition for the treatment of cancers

Legal Events

Date Code Title Description
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20170215

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20180207

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20190208

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20210220

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20210220